{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_codes_USAN in USAN (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03196843: Phase 4 Interventional Unknown status Head and Neck Squamous Cell Carcinoma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Raltitrexed belongs to a group of medicines known as antimetabolites. It is used to treat cancer of the colon and rectum. It may also be used to treat other kinds of cancer, as determined by your doctor. Raltitrexed blocks an enzyme needed by the cell to live. This interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by raltitrexed, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Raltitrexed inhibits thymidylate synthase (TS) leading to DNA fragmentation and cell death. It is transported into cells via a reduced folate carrier. Inside the cell Raltitrexed is extensively polyglutamated, which enhances thymidylate synthase inhibitory power and duration. Inhibition of this enzyme results in decreased synthesis of thymidine triphosphate which is required for DNA synthesis. Raltitrexed is used for the treatment of malignant neoplasm of colon and rectum. Although raltitrexed is not approved by the US FDA, the drug was licensed in Canada and some European countries.
Status:
US Approved Rx
(2004)
Source:
BLA125104
(2004)
Source URL:
First approved in 2004
Source:
BLA125104
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761073
(2019)
Source URL:
First approved in 1998
Source:
BLA103792
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA020898
(1998)
Source URL:
First approved in 1998
Source:
BLA020898
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761140
(2020)
Source URL:
First approved in 1997
Source:
BLA103705
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2024)
Source:
NDA218771
(2024)
Source URL:
First approved in 1987
Source:
PARATHAR by SANOFI AVENTIS US
Source URL:
Class:
PROTEIN
Conditions:
Teriparatide was manufactured under the brand name FORTEO. FORTEO contains recombinant human parathyroid hormone (1-34), [rhPTH(1-34)], which has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone, that regulates calcium and phosphate in the body. FORTEO is indicated for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. In addition, Forteo is used for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk for fracture. The biological actions of teriparatide is mediated through binding to specific high-affinity cell-surface receptors. Teriparatide is not expected to accumulate in bone or other tissues.
Class:
PROTEIN
Class:
PROTEIN
Class:
PROTEIN
